$ENVA

Fisher David sold $1.2M of ENVA

Fisher David (Executive Chairman) sold 7,180 shares of Enova International, Inc. (ENVA) at $160.37 ($1.15M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher David
Published May 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralMed
01

Why it matters

The disclosure provides information about insider liquidity and potential sentiment, but the presence of a pre-arranged 10b5-1 plan generally lowers the probability of a fundamental negative signal.

02

Market read

ENVA receives a Form 4 showing an executive chairman open-market sale (~$1.15M) under 10b5-1, which may cause limited short-term sentiment pressure.

03

What to watch

Traders may overreact to the headline dollar amount; the key nuance is the pre-arranged plan and the relatively small post-sale ownership change versus total shares.

Relevance 8/10Timing: Potential short-term sentiment/positioning impact as traders digest the Form 4 filing; no immediate catalyst beyond disclosure.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc. (ENVA).

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Enova executive chairman David Fisher sold $1.15M of ENVA shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside/volatility risk around the filing date; longer-term impact likely limited.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal—this is company-specific insider activity without broader sector/regulatory signals.

None indicated; US-listed issuer disclosure only.

None indicated; no cross-border deal or operational update mentioned.

Counterpoint

The sale may reflect routine liquidity/portfolio rebalancing under a 10b5-1 plan rather than negative expectations.

Key entities

  • Enova International, Inc.

    Subject of the Form 4 insider sale by executive chairman David Fisher.

  • David Fisher

    Executive Chairman who sold 7,180 ENVA shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ENVAMed

Citizens raises Enova stock price target on strong growth outlook

Citizens raised its price target for Enova International (NYSE:ENVA) to $220 from $215, citing strong growth and stable credit quality. The company reported 30%+ originations growth and 30%+ EPS growth for multiple quarters. Enova's stock has gained 55% over the past year, but may be overvalued according to InvestingPro's Fair Value analysis. Citizens also increased its 2027 adjusted EPS estimate to $22.03 from $21.47, expecting more aggressive share buybacks.

$ENVAMedAI 8/10

Enova International Inc (ENVA) Q3 2026 Earnings Call Highlights: Revenue Tops $1 Billion

Enova International Inc (ENVA) reported Q3 2026 revenue exceeding $1 billion, up 26% YoY, with adjusted EPS increasing 33% to $4.48. Originations grew 31% YoY to $2.6 billion, marking 12 consecutive quarters of at least 20% growth. The company noted increased marketing expenses and SMB delinquencies, while withdrawing bank applications. Management expects Q4 2026 revenue to rise 25% YoY with stable margins.

$ENVAMedAI 8/10

Enova Tops $1 Billion Quarterly Revenue as Online Lending

Enova reported Q3 2026 revenue of $1.1 billion, up 26% YoY, with originations and adjusted EPS also rising significantly. Net charge-off ratio improved to 8.1%. The company's portfolio reached $5.9 billion, with small business products comprising 68%. Enova withdrew its bank regulatory applications for Grasshopper Bancorp acquisition, citing regulatory misalignment, but expects continued growth.

$ENVAMed

What Enova International (ENVA) Said on Its Q3 Earnings Call

Enova International (ENVA) reported Q3 improvements in net charge-off ratios and revenue margins, with consolidated net revenue margin at 61%. The company expects Q4 margins between 55% and 60%. Marketing expenses rose to 23% of revenue, supporting growth. Enova has $1.3B in liquidity and repurchased 243,000 shares. It forecasts 25% revenue growth and 30-35% adjusted EPS increase for Q4. The company is exploring new product opportunities in consumer and small-business lending.

$ENVAMedAI 8/10

Enova (ENVA) Q3 2026 Earnings Call Transcript

Enova (ENVA) reported Q3 2026 earnings with 26% revenue growth to over $1 billion, driven by 30% portfolio growth. Consumer and small business originations increased 37% and 28% respectively. Adjusted EPS rose 33%. Net charge-off rates improved, with the consolidated rate at 8.1%. The company expects strong Q4 results, citing resilient macroeconomic conditions and consumer spending.